Alirocumab: an investigational treatment for hypercholesterolemia

Q Medicine
K. Ray
{"title":"Alirocumab: an investigational treatment for hypercholesterolemia","authors":"K. Ray","doi":"10.2217/clp.14.56","DOIUrl":null,"url":null,"abstract":"Kausik Kumar Ray is visiting Professor of Cardiovascular Disease Prevention in the Division of Cardiovascular Sciences, University of London, London, UK. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, UK, his MD (2004) at the University of Sheffield, UK, a postdoctoral fellowship at Harvard Medical School, Massachusetts, USA, and finally an MPhil in Epidemiology (2007) from the University of Cambridge, UK. A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Professor Ray is also a member of the British Cardiovascular Society. Professor Ray has been the national lead investigator, served on the committees or been Principal Investigator for several major medical trials, including T-EMERGE 8, SOLID TIMI 52, SAVOR TIMI 54, DAL OUTCOMES II, DAL-ACUTE, ODYSSEY and DECLARE TIMI 58. Professor Ray's research interests have focused on the prevention and red...","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"32 1","pages":"12 - 9"},"PeriodicalIF":0.0000,"publicationDate":"2015-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lipidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/clp.14.56","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Kausik Kumar Ray is visiting Professor of Cardiovascular Disease Prevention in the Division of Cardiovascular Sciences, University of London, London, UK. Professor Ray received his medical education (MB ChB, 1991) at the University of Birmingham Medical School, UK, his MD (2004) at the University of Sheffield, UK, a postdoctoral fellowship at Harvard Medical School, Massachusetts, USA, and finally an MPhil in Epidemiology (2007) from the University of Cambridge, UK. A Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Royal College of Physicians, Professor Ray is also a member of the British Cardiovascular Society. Professor Ray has been the national lead investigator, served on the committees or been Principal Investigator for several major medical trials, including T-EMERGE 8, SOLID TIMI 52, SAVOR TIMI 54, DAL OUTCOMES II, DAL-ACUTE, ODYSSEY and DECLARE TIMI 58. Professor Ray's research interests have focused on the prevention and red...
Alirocumab:一种实验性治疗高胆固醇血症的药物
Kausik Kumar Ray是英国伦敦大学心血管科学系心血管疾病预防客座教授。Ray教授1991年在英国伯明翰大学医学院获得医学硕士学位,2004年在英国谢菲尔德大学获得医学博士学位,并在美国马萨诸塞州哈佛大学医学院获得博士后奖学金,2007年在英国剑桥大学获得流行病学硕士学位。Ray教授是美国心脏病学会、欧洲心脏病学会、美国心脏协会和皇家医师学会的会员,也是英国心血管学会的成员。Ray教授曾担任国家首席研究员,在多个主要医学试验中担任委员会成员或首席研究员,包括T-EMERGE 8、SOLID TIMI 52、SAVOR TIMI 54、DAL OUTCOMES II、DAL- acute、ODYSSEY和DECLARE TIMI 58。雷教授的研究兴趣集中在预防和预防…
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Lipidology
Clinical Lipidology 生物-生化与分子生物学
CiteScore
0.44
自引率
0.00%
发文量
0
审稿时长
6-12 weeks
期刊介绍: The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信